Empty AAV capsids are known contributors of immunogenicity in gene therapy products. Reducing them below 10% during downstream process is ...
https://www.google.com/url?rct=j&sa=t&url=https://bioprocessintl.com/sponsored-content/analytical-tools-to-improve-production-of-full-capsids-in-initial-stages-of-aav-process-development/&ct=ga&cd=CAIyGmEyNDJjNTAxZWU3OTQyNzI6Y29tOmVuOlVT&usg=AOvVaw0Glmz9YrmfVx7OVj_Qoah1
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.